Moneycontrol
Get App
you are here: HomeNewsBusiness
Last Updated : May 31, 2017 11:11 AM IST | Source: PTI

Glenmark gets USFDA nod for ADHD drug

"Glenmark Pharmaceuticals Inc, USA has been granted final approval by the United States Food & Drug Administration (U S FDA) for Atomoxetine Capsules USP, 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg, the generic version of Strattera Capsules of Eli Lilly and Company," Glenmark Pharmaceuticals said in a BSE filing.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Glenmark Pharmaceuticals has received final approval from the US health regulator for generic version of Strattera Capsules, used in treatment of attention-deficit/hyperactivity disorder (ADHD).

"Glenmark Pharmaceuticals Inc, USA has been granted final approval by the United States Food & Drug Administration (U S FDA) for Atomoxetine Capsules USP, 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg, the generic version of Strattera Capsules of Eli Lilly and Company," Glenmark Pharmaceuticals said in a BSE filing.

According to IMS Health sales data for the 12 months to April 2017, the Strattera capsules achieved annual sales of approximately USD 1.1 billion, Glenmark said.

Close

The company's current portfolio consists of 117 products authorised for distribution in the US marketplace and 67 Abbreviated New Drug Applications (ANDA) pending approval with the USFDA.

Glenmark Pharmaceuticals shares were trading at Rs 632.95 on the BSE, up 1.39 per cent, on BSE.

Get access to India's fastest growing financial subscriptions service Moneycontrol Pro for as little as Rs 599 for first year. Use the code "GETPRO". Moneycontrol Pro offers you all the information you need for wealth creation including actionable investment ideas, independent research and insights & analysis For more information, check out the Moneycontrol website or mobile app.
First Published on May 31, 2017 11:05 am
Loading...
Sections
Follow us on
Available On
PCI DSS Compliant